These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29059782)

  • 1. Re: Cost Profiles and Budget Impact of Rechargeable versus Non-Rechargeable Sacral Neuromodulation Devices in the Treatment of Overactive Bladder Syndrome.
    Wein AJ
    J Urol; 2017 Nov; 198(5):986-987. PubMed ID: 29059782
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
    Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB
    Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder.
    Albabtain M; Chughtai B; Cho A; Elterman D
    Ther Deliv; 2021 May; 12(5):353-362. PubMed ID: 33821666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Detailed Analysis of Adverse Events and Surgical Interventions in a Large Prospective Trial of Sacral Neuromodulation Therapy for Overactive Bladder Patients.
    Wein AJ
    J Urol; 2018 Apr; 199(4):898. PubMed ID: 29642366
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation.
    Martinson M; MacDiarmid S; Black E
    J Urol; 2013 Jan; 189(1):210-6. PubMed ID: 23174264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience.
    Chartier-Kastler E
    BJU Int; 2008 Feb; 101(4):417-23. PubMed ID: 18070181
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation: M. Martinson, S. MacDiarmid and E. Black J Urol 2013; 189: 210-216.
    Barnett G; Ockrim J
    J Urol; 2013 Oct; 190(4):1444-5. PubMed ID: 23886880
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.
    Tahseen S
    Int Urogynecol J; 2018 Aug; 29(8):1081-1091. PubMed ID: 29302716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacral neuromodulation - when and for who.
    Mass-Lindenbaum M; Calderón-Pollak D; Goldman HB; Pizarro-Berdichevsky J
    Int Braz J Urol; 2021; 47(3):647-656. PubMed ID: 33621015
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Guzman-Negron et al-"Sacral Neuromodulation Lead Twisting Causes Migration and Loss of Efficacy".
    Roth TM
    Female Pelvic Med Reconstr Surg; 2021 May; 27(5):334-335. PubMed ID: 33909601
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: A Prospective, Multicenter Study of a Novel, Miniaturized Rechargeable Sacral Neuromodulation System: 12-Month Results from the RELAX-OAB Study.
    Wein AJ
    J Urol; 2020 Mar; 203(3):467-468. PubMed ID: 31829816
    [No Abstract]   [Full Text] [Related]  

  • 12. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: is on-demand sacral neuromodulation in patients with OAB syndrome a feasible therapy regime?
    Wein AJ
    J Urol; 2013 Feb; 189(2):610-1. PubMed ID: 23312179
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Results of a Prospective, Randomized, Multicenter Study Evaluating Sacral Neuromodulation with InterStim Therapy Compared to Standard Medical Therapy at 6-Months in Subjects with Mild Symptoms of Overactive Bladder.
    Wein AJ
    J Urol; 2015 Oct; 194(4):1051-2. PubMed ID: 26382800
    [No Abstract]   [Full Text] [Related]  

  • 15. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction.
    Cohn JA; Kowalik CG; Kaufman MR; Reynolds WS; Milam DF; Dmochowski RR
    Expert Rev Med Devices; 2017 Jan; 14(1):3-14. PubMed ID: 27915486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacral Neuromodulation and Twiddler's Syndrome.
    Roth TM
    Urology; 2018 Jun; 116():e1-e2. PubMed ID: 29574121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacral neuromodulation with an implantable pulse generator in children with lower urinary tract symptoms: 15-year experience.
    Groen LA; Hoebeke P; Loret N; Van Praet C; Van Laecke E; Ann R; Vande Walle J; Everaert K
    J Urol; 2012 Oct; 188(4):1313-7. PubMed ID: 22902022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
    Leong RK; De Wachter SG; van Kerrebroeck PE
    Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
    Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
    Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.